The positive safety data from the in vitro CYP450 and transporter-mediated drug-drug interaction studies of Mazindol indicate a low risk for drug-drug interaction. This is beneficial for NLS Pharmaceutics as it may lead to fewer regulatory hurdles and a smoother approval process for the drug. Additionally, it may increase the potential market for the drug, as it can be safely combined with other medications. This positive news is likely to have a short-term positive impact on the company's stock price.